On October 9, WUXI APPTEC fell 3.16% in regular trading, trading at 202.2 HKD with turnover of 5.2 billion HKD.

The decline was driven by broad pressure across the Hong Kong pharmaceutical sector, with major CXO and innovative drug names trading lower. WUXI BIO fell 3.33%, GENSCRIPT BIO fell 2.95%, WUXI XDC fell 3.16%, and XTALPI fell 3.64%, dragging WUXI APPTEC lower in sympathy.

Recent gains had been fueled by the full conversion of its 6.78 billion yuan zero-coupon convertible bonds, active institutional accumulation by firms including FMR LLC and JPMorgan, and improving CXO sector fundamentals. After hitting a record high of 219.2 HKD on October 7, short-term profit-taking pressure has emerged.

WUXI APPTEC is a leading global provider of integrated, end-to-end R&D and manufacturing services for the pharmaceutical and life sciences industry, serving thousands of partners across more than 30 countries.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)